Mrs. Vicky Lee Parks, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 111 S 3rd Ave, Piggott, AR 72454 Phone: 870-598-0306 Fax: 870-598-0328 |
News Archive
The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.
Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay.
The Conference Board of Canada, the Heart and Stroke Foundation and the Canadian Cardiovascular Society will hold a press conference on Monday, February 8 to announce the findings of the report, The Canadian Heart Health Strategy: Risk Factors and Future Cost Implications.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
As part of the largest international research effort ever made to combat tuberculosis, a team of Johns Hopkins and Brazilian experts has found that preventive antibiotic therapy for people with HIV lowers this group's chances of developing TB or dying.
› Verified 3 days ago